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Photoprotection for skin of all color:
Consensus and clinical guidance from an
expert panel
Darrell S. Rigel, MD, MS,a Susan C. Taylor, MD,b Henry W. Lim, MD,c Andrew F. Alexis, MD, MPH,d
April W. Armstrong, MD, MPH,e Zelma C. Chiesa Fuxench, MD, MSCE,b Zoe D. Draelos, MD,f and
Iltefat H. Hamzavi, MDc
New York, New York; Philadelphia, Pennsylvania; Detroit, Michigan; Los Angeles, California; and High
Point, North Carolina
The negative effects of sun exposure have become better accepted among health care professionals and
the lay public over recent decades. Most attention has been focused on the effects of UV light, particularly
UVB wavelengths (290-320 nm). Accordingly, products to protect skin from sunlight-associated harm
(sunscreens) have been developed to minimize UVB exposure. The effects of longer wavelengths,
including UVA (320-400 nm) and visible light (VL, 400-700 nm), are increasingly appreciated. VL accounts
for approximately half of the solar radiation that reaches the earth’s surface and understanding of its effects
on the skin is improving. Studies have shown that VL can induce hyperpigmentation in individuals with
dark skin types (Fitzpatrick skin types IV-VI). In addition, VL can contribute to the exacerbation of
pigmentary disorders, including melasma. Because these findings are relatively new, there are gaps in
understanding the needs for photoprotection and guidance for clinicians. A panel of dermatologists and
photobiologists was convened to develop consensus recommendations and clinical guidance about
sunscreen use relevant to the current understanding of risks associated with sun exposure using a modified
Delphi method. ( J Am Acad Dermatol 2022;86:S1-8.)
Key words: photoprotection; skin of color; sunscreens; ultraviolet light; visible light.

INTRODUCTION
There is general agreement that photoprotection is
needed to minimize the risks of sun exposure, which
can range from sunburn to early skin aging and skin
cancers. According to the most recent 2019 recommendations from the United States Food and Drug
Administration (FDA), photoprotection encompasses
the following1: (1) seek shade when outdoors; (2) be
cautious about sun exposure, particularly during
midday (10 AM to 2 PM) when light is most intense;
(3) cover up with clothing, wide brimmed hat, and
sunglasses; and (4) apply broad-spectrum sunscreens
with sun protection factor (SPF) 30 or above, and
repeat applications frequently (1 or more times every
2 hours) when outdoors.1 The American Academy of

Dermatology recommends sunscreens that have an
SPF of 30 or higher and are water resistant and broad
spectrum, along with sun protective clothing, hat,
glasses, and sun avoidance. In this article, the term
‘‘photoprotection’’ refers to all of the above strategies.
Sunlight includes wavelengths in the UVB and
UVA ranges (UVB, 290-320 nm; UVA2, 320-340 nm;
and UVA1, 340-400 nm) and visible light (VL: 400700 nm).2,3 Because the damaging effects of UVB
were recognized first (sunburn), sunscreens were
developed primarily to prevent UVB from penetrating skin.4 The SPF of a sunscreen, defined as ‘‘the
level of sunburn protection’’ assesses damage caused
primarily by UVB and, to a lesser degree, UVA2 but
does not provide information about protective ability
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against other wavelengths of light.1,4 SPF was adopThe purpose of this supplement is to highlight
ted by the FDA in 1978.
emerging data and current knowledge gaps surCutaneous structural damage due to UVA exporounding the use of sunscreen, particularly for
sure was first reported by Kligman5 in 1969, who
patients with dark skin types. To synthesize existing
information and supplement areas where the evicoined the term ‘‘photoaging’’ in response to his
dence base is sparse, the group reviewed the
findings. In 2011, the FDA changed the definition of
literature and performed a modified Delphi method
‘‘broad-spectrum sunscreen’’ to incorporate UVA
to reach agreement on asprotection due to increasing
pects of sunscreen use that
evidence supporting the
CAPSULE SUMMARY
could update the knowledge
damaging effects of UVA
base and provide consensus
and because of concerns
UV filters have traditionally focused on
guidance. Consensus stateabout the ‘‘potential for inadthe ultraviolet spectrum.
ments are provided here,
equate UVA protection in
along with a bulleted listing
marketed sunscreen prodVisible light can induce
of key supportive points, as
ucts.’’1 To date, the FDA has
hyperpigmentation in individuals with
well as guidance for individnot incorporated a measure
dark skin types and contribute to the
ualizing recommendations
of the protective capacity of
exacerbation of pigmentary disorders.
about sunscreens for patients.
sunscreens against VL, and
Three detailed reviews are
there is no internationally
also included with this supplement. These provide an
agreed upon rating system for either UVA or VL. A
in-depth examination of the current literature on
wide variety of UVB filters are currently approved by
specific topics of relevance. Rigel et al present
the FDA but only 2 of those approved offer longwave
Photoprotection for All: Current Gaps and
UVA protection: zinc oxide and avobenzone.4
Opportunities, Lim et al discuss the Impact of Visible
While existing guidance from the American
Light on Skin Health: The Role of Antioxidants and Free
Academy of Dermatology and FDA focuses primarRadical Quenchers in Skin Protection, and Taylor et al
ily on UV risks, there is emerging evidence about
review Misconceptions of Photoprotection in Skin of
the importance of VL. Approximately 50% of sunColor.
light is in the visible spectrum (wavelengths 400700 nm), and it is increasingly appreciated that
these longer wavelengths have biologic effects on
METHODS TO ACHIEVE CONSENSUS
the skin.6-8 The cutaneous effects of VL include
The Delphi method, a structured decision-making
pigment darkening (Fitzpatrick skin type [FST ] IVmethod, was used to arrive at consensus statements
VI) and erythema (FST I-III), with the former being
regarding aspects of photoprotection that have not
more long-lasting and intense than that induced by
been addressed specifically in existing guidance.
UVA1.7,9 The clinical relevance of VL was noted
Based on the literature, a list of key statements was
when studies of women with melasma showed that
formulated by the group. These were shared via an
sunscreens had variable efficacy in protecting from
online survey process and panelists rated their level
relapse due to differences in their coverage of VL
of agreement with each statement based on a 5-point
wavelengths.10 Further, investigation with LED
Likert scale from ‘‘strongly agree’’ to ‘‘strongly
lights showed that the lower range of VL (bluedisagree’’ in an anonymous fashion. Panelists were
violet light or approximately 415 nm) was primarily
also asked to expand upon their response with a
responsible for inducing pigmentation in dark skin
brief written statement. Results were tallied after the
types.10,11
first round and shared with the group, along with
Thus, while all skin types should be protected from
compiled comments. At this stage, the panel memUV radiation, VL is a concern, especially for individuals
bers had the opportunity to revise their answers
with dark skin types. There also appears to be a synergy
while considering compiled comments. Based on
between UV and VL, where VL seems to accentuate the
feedback, the statements were modified and a seceffects of long wavelength UVA.12 To date, photoond round of rating was performed, also online. For
protection against VL relies primarily on sun avoidance
the final round, panelists met in person via videoand use of protective clothing, hats, and glasses. UV
conferencing to review and discuss each statement,
filters approved for use in sunscreen formulations in
thereby arriving at the final consensus statements. At
the United States do not protect against VL; however,
each round, consensus was defined as a supermatinted sunscreen does. In addition, new ingredients,
jority (7 or 8 of the 8 panelists rating the statement as
such as antioxidants and radical quenchers, are also
‘‘agree’’ or higher). Evince Communications, LLC was
being investigated for VL protection.4
the facilitator of the Delphi process.
d

d

J AM ACAD DERMATOL

Rigel et al S3

VOLUME 86, NUMBER 3

Abbreviations used:
FDA:
FST:
SPF:
UV:
UVA:
UVB:
VL:

Food and Drug Administration
Fitzpatrick skin type
Sun protection factor
Ultraviolet
Ultraviolet A
Ultraviolet B
Visible light

d

NEW PERSPECTIVES ON SUNSCREEN USE
Consensus: UVA/UVB protection alone is not
sufficient for overall skin health, especially in
dark skin types
d The proliferation of sunscreen products demonstrates the increase in global awareness and demand for sun protection among consumers.4
d It is important for clinicians to understand the
safety and effectiveness of existing sunscreen filters, specifically regarding non-UVB wavelengths.4
d This may be especially true when recommending
photoprotection
for
the
purposes
of
protection against disorders of hyperpigmentation, including melasma or post-inflammatory
hyperpigmentation.7,10,11,13
Consensus: Emerging types of
photoprotection should be considered
UV and VL generate reactive species (ie, reactive
oxygen and nitrogen species) that contribute to skin
damage and skin dyspigmentation (eg, hyperpigmentation, melasma, uneven skin tones, photoaging, and post-inflammatory hyperpigmentation).
Therefore, emerging types of photoprotection,
including those containing stable and physiologically active oral and/or topical antioxidants, should
be considered.
d While the FDA regulates sunscreens as over-thecounter drugs, the European Commission regulates sunscreens as cosmetics.4 In comparison to
the 16 FDA-approved sunscreen filters, the European Commission currently has 27 approved
filters, primarily due to more approved UVA
filters. Thus, consumers in the United States
have less access to sunscreens with broadspectrum filters compared to Europe.
14
d In 2015, Diffey et al
compared UV protection
afforded by 4 sunscreens in the United States and
4 in Europe, each with SPF of 50 or more. The
ability of sunscreens in the United States, which
included modern UVA filters, to prevent UVA from
reaching skin was approximately 3-fold lower
than that of the European sunscreens.14 This
prompted the FDA to change the UVA protection

d

standard, removing the worst-performing sunscreens from the market.4
Inclusion of antioxidants and other ingredients in
sunscreen to provide protection against UVA and
VL wavelengths is an emerging area of research
and development. The rationale for including
antioxidants in sunscreens stems from their ability
to scavenge free radicals, which can mediate
oxidative skin damage.15-17 The article ‘‘Impact
of Visible Light on Skin: The Role of Antioxidants
and Free Radical Inhibitors in Photoprotection,’’
in this supplement details currently existing evidence in the literature.
Discussion of products with antioxidants and,
potentially, use of oral antioxidants should be
considered when counseling patients with dark
skin types about their needs for photoprotection. However, it should be noted that currently
there are no standard assessments to evaluate
their biologic activity once applied to the skin.
It is also important to be aware that some
antioxidants are included in sunscreen formulations to prevent lipids from being oxidized
but
are
not
biologically
relevant
in
photoprotection.

Consensus: There are misconceptions
surrounding the need for the use of
photoprotection for dark skin types
d Differences in the use of sunscreens and photoprotective practices between individuals with light
skin (FSTs I-III and those with dark skin (FSTs IVVI) have been documented, showing individuals
with dark skin, or skin of color (SOC, [FSTs III-IV]),
to be less likely to use sunscreens and practice
other photoprotective behaviors despite having
experienced sunburns.18
d Further, many individuals with SOC are unaware of the need for photoprotection, due to
the belief that their naturally dark skin tone is
more capable of providing protection against
photodamage.19,20 While progress has been
made in educating patients with SOC about
the need for photoprotection, more efforts are
needed. The article ‘‘Misconceptions of Photoprotection in Skin of Color’’ in this supplement
addresses this topic.
Consensus: There are major gaps in
photoprotection products for both UV and VL
d Because the original focus was on UV damage,
sunscreens were developed to protect against the
effects of UV radiation, primarily UVB.4
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d

d

There is a need for a standardized method to
assess UVA and VL protection.
Existing systems to evaluate UVA protection
include the European Commission-recommended
UVA-PF, the FDA-recommended critical wavelength method, and the Boots star rating system
used in the United Kingdom.21
Among filters approved by the FDA, zinc oxide and
avobenzone absorb in the longwave UVA spectrum;
unfortunately, avobenzone is not photostable.
While other photostable broad-spectrum UV filters are available in many parts of the world, these
are not currently approved in the United States.22

RECOMMENDATIONS FOR CLINICAL
MANAGEMENT
Consensus: Photoprotection education and
evaluation should be included as part of
overall patient skin assessments
d Dermatologists are well aware of the need for
photoprotection; however, there are gaps in
educating patients with SOC about the risks of
sun exposure. As recently as 2021, it was found
that dermatologists were less likely to counsel
patients with SOC about photoprotection, and
42.9% of the dermatologist respondents indicated
never/rarely/only individualizing sunscreen recommendations according to patient skin phototype.23 This highlights a growth opportunity
within dermatology to gain familiarity with sunscreen types and formulations oriented toward
use by patients with SOC.23 The literature about
educational efforts and evaluation of photoprotection in SOC are discussed in detail in the
article, Photoprotection for All: Current Gaps
and Opportunities, elsewhere in this supplement.
Consensus: A personalized photoprotection
regimen should be recommended for all FSTs
d Photoprotection recommendations should be discussed with the patient and then implemented
based on joint decision-making about potential
risks of exposure and preferences. Factors to
consider include FST, geography (extent of sun
exposure, humidity, etc), and lifestyle. Some
suggestions for tailoring sunscreen recommendations are provided in Table I, while Table II shows
ingredients that may offer potential benefit for
individual skin diseases/characteristics.24-28
d Additional considerations that may affect counseling discussions with patients are presented in
Table III.29
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RECOMMENDATIONS FOR EDUCATIONAL
INITIATIVES
Consensus: Additional training/education for
dermatologists and other clinicians in
photoprotection and impact of VL is needed
d This is an evolving area of research, but it is
important for clinicians to know about the biologic effects of VL to be better equipped to
counsel patients.
d Clinicians with a good understanding of photoprotection can potentially improve adherence via
measures to minimize risks associated with light
exposure. For example, personalized intervention
mapping has been shown to improve photoprotective behaviors in adults with xeroderma pigmentosum, a population at high risk for skin
cancer.30
Consensus: Additional research in
photoprotection and the biologic effects of
sunlight is needed
d There is a need for broader understanding of the
effects of light on skin. While the understanding of
the effects of UVB is fairly advanced, knowledge of
the effects of UVA and especially VL exposure
remains limited and mechanisms of cutaneous
damage are incompletely understood.31
d While prior studies on how tissues interact with
light have provided insights into skin aging,
cutaneous cancers, and other dermatologic diseases, more research is still urgently needed.
d Advancing our understanding in this area can
then lead to advances in sunscreen ingredients,
which, in turn, could translate to improved photoprotection and perhaps influence patient acceptance and utilization.
Consensus: Patients should be educated about
the potential role of VL’s impact on overall
skin health
Patient education about the potential impact of VL
on skin health includes induction and/or exacerbation of multiple skin conditions: hyperpigmentation,
melasma, post-inflammatory hyperpigmentation,
uneven skin tone, and photoaging, especially in FST
IV-VI.
d As indicated in this publication and the remainder
of the supplement, there are nuances in photoprotection that can be individualized based on
patients’ preferences, lifestyle, and characteristics.
d The current array of sunscreen products available
allow selection of a formulation that can enhance
adherence while protecting overall skin health.
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Table I. Individualizing sunscreen recommendations
Patient characteristic

Atopic dermatitis/
sensitive skin24

Suggestions
d

Although controlled sun exposure has benefits for some patients with atopic dermatitis,
exposure in others may result in impaired skin barrier function
B Patients with atopic dermatitis may experience photoaggravation (long-lasting erythema)/
photosensitivity

d

Optimize skin care regimen with gentle cleanser and moisturizer, particularly moisturizers with
SPF
Consider mineral sunscreens because they have low absorption (examples: titanium dioxide, zinc
oxide)
Avobenzone and octocrylene are rare sensitizers and considered safe
Ingredients to avoid due to potential for contact dermatitis:
B Benzophenone-3 (oxybenzone)
B Patient-specific triggers

d

d
d

Concern about
photodamage/
premature aging26

d

d
d

Oily and/or acneprone skin25

d
d

d

d
d
d

Hyperpigmentation28

d
d

d
d

Photosensitivity28

d

d
d

Rosacea28

d

d

Daily use of broad-spectrum photostable sunscreen on all sun-exposed areas and protective
clothing and hats as often as practical
After-sun products to help repair skin damage and support skin regeneration
Consider retinol-containing product at nighttime to increase cell turnover
When possible, cleanse skin prior to applying sunscreen
Choose non-comedogenic, lightweight, non-greasy formulations that absorb quickly (examples:
gel or liquid formulations)
Choose products with matte finish to avoid adding a shiny appearance; powder sunscreen also
may be useful
Avoid fragrances and oils (example: coconut oil)
Consider oil-absorbing moisturizers with SPF
Consider mineral sunscreens, because they have low absorption (examples: titanium dioxide,
zinc oxide)
Most common in FST IV-VI
Sunscreen should be broad-spectrum and protect against VL and may benefit from the addition
of anti-inflammatory agents such as licochalcone A and glycyrrhetinate, although the efficacy of
these agents is still under evaluation
Limit sun exposure when possible
For PIH, opaque dressings for 15 days may be beneficial
Consider mineral sunscreens because they have low absorption (examples: titanium dioxide, zinc
oxide)
Apply products containing retinol/retinoids at night
Review topical and systemic medication use
Daily use of broad-spectrum sunscreens to minimize effect of UV radiation and heat on
erythema and telangiectasia
Select sunscreens containing dimethicone or cyclomethicone to reduce irritation

FST, Fitzpatrick skin type; PIH, postinflammatory hyperpigmentation; SPF, sun protection factor; UV, ultraviolet; VL, visible light.

LIMITATIONS AND PANEL SELECTION
The final 9 consensus statements developed via
the modified Delphi method could be organized into
3 categories: (1) new perspectives on sunscreen use;
(2) recommendations for clinical management; and
(3) recommendations for educational initiatives.
Clinicians may consider implementation of the
panel’s recommendations on photoprotection, in
particular expanding patient awareness for the
need for photoprotection against both UV and VL
in all skin tones. Nevertheless, there are limitation to
consider, which provide direction for expanded
discussions and recommendations.

The panel that was developed was selected based
on several criteria and knowledge of the subject area
with the objective aiming to bring together a
multidisciplinary group of leaders in the fields of
dermatologic impacts in SOC, photoprotection, and
photobiology, representing both academic and private practice. Additionally, inclusion of representatives from multiple regions of the United States were
included, as well as years of practice to maximize
views of the subject areas discussed; however, the
small size of the panel (N = 8) should be noted. The
major gaps discussed and presented, though
focusing on gaps in photoprotection in SOC, aimed
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Table II. Ingredients that may offer potential benefits in specific settings
Ingredient with potential benefit

Alpha glucosylrutin
Bisabolol
Ceramide
Cyclomethicone/dimethicone
Dexpanthenol (anti-irritant/
itch)
Ectoin
Glycyrrhetinate
Green tea
Hyaluronic acid
Lactic acid
Licochalcone A
Lipid absorbing pigments
(tints)
Occlusive agents (dimethicone)
Niacinamide
Thiamidol
Vitamin C
Vitamin E/alpha-tocopherol

Acne/oily skin

Atopic dermatitis/
sensitive skin

Hyperpigmentation

Photoaging

Photosensitivity

Rosacea

Yes
Yes
Yes

Yes

Yes
Yes

Yes
Yes
Yes
Yes
Yes
Yes
Yes

Yes
Yes

Yes

Yes

Yes
Yes

Yes
Yes

Yes
Yes

Yes
Yes

Yes

Yes

Yes
Yes
Yes
Yes
Yes

Yes
Yes

Table III. Counseling men about skin and
sunscreen29
d

Educate male patients that their skin is different from
women’s skin, and should have specific care. Things to
discuss include:
B In general, male skin is approximately 20% thicker
than female skin and contains more collagen. As a
result, it ages differently and signs of aging may
appear later in men but may also occur more
rapidly after onset compared with women.
B Sebaceous glands may be more active and larger,
resulting in oilier skin.
B Shaving makes facial skin stressed and irritated and
can be a factor in poor tolerance of sunscreens.

d

Surveys indicate that men are less likely to use sunscreen and protective clothing or hats than women. It is
important to discuss the need for photoprotection
along with a skin care regimen to protect skin.

to discuss overall gaps in photoprotection for all skin
tones, especially from UVA and VL, which is
increased due to FDA guidance on sunscreens in
the United States, thus the inclusion of only dermatologists from the United States on in the panel.
However, the selection of only a panel of experts
from the United States was not meant to assess
photoprotection issues and gaps worldwide, nor
areas with high concentration of SOC residents, but
rather to increase awareness about the importance
for photoprotection for skin of all color.

CONCLUSIONS
It is increasingly recognized that sun care should
be personalized based on FST, degree of sun
exposure, and utility of individual sunscreen formulations and ingredients. The knowledge base surrounding the effects of UV and VL on skin is
expanding, but gaps in understanding remain for
both clinicians and, more prominently, patients. This
is particularly true for individuals with dark skin
types, who are at risk for pigmentation problems
from VL. These individuals often believe that the
higher degree of melanin in their skin protects them
from the harmful effects of sun exposure; thus, there
is a need not only to educate but also to dispel myths
about sun care needs. New approaches, including
novel ingredients and formulations, more balanced
UVB, UVA, and VL protection, are under investigation to address gaps in care for specific skin types.
The authors thank Rene Alvarez, PhD and Valerie
Sanders from Evince Communications for providing editorial support including development of the rough draft of
the manuscript based exclusively on the results of the
modified Delphi questionnaires, group discussions, and
input from the corresponding authors. This assistance was
funded via unrestricted educational funding from
Beiersdorf, Inc, which supported this work. The final
version solely represents the views of the authors and
was approved by each author prior to submission.
Conflicts of interest

Dr Taylor has served as an investigator for Concert
Pharmaceuticals, Croma-Pharma GmbH, Eli Lilly and

J AM ACAD DERMATOL
VOLUME 86, NUMBER 3

Company, Immune Tolerance Network, and Pfizer; as a
consultant/speaker/advisory board member for AbbVie,
Arcutis Biotherapeutics, Beiersdorf Inc, Biorez, Inc,
CannTec, Evolus, Galderma Laboratories, GloGetter Inc,
L’Oreal USA, Inc, LuminDX, Medscape/WebMD, Johnson &
Johnson Consumer Products, Scientis, and Vichy
Laboratories; and has received book royalties from
McGraw Hill. Dr Lim has served as investigator (grant to
institution) for Incyte, L’Oreal, Pfizer, and Patient-Centered
Outcomes Research Institute; as a consultant for Pierre Fabre,
ISDIN, Ferndale, La Roche-Posay, and Beiersdorf; and as a
speaker in a general education session for La Roche-Posay
and Cantabria Labs. Dr Alexis has received grant/research
support from Leo Pharma, Novartis, Almirall, Bristol Myers
Squibb, Amgen, Menlo, Galderma, Valeant (Bausch Health),
Cara, and Arcutis Biotherapeutics; and has served as a
consultant/speaker for Leo Pharma, Galderma, Pfizer,
Sanofi-Regeneron, Dermavant, Beiersdorf, Valeant, L’Oreal,
Bristol Myers Squibb, Bausch Health, UCB Pharma, Vyne
Therapeutics, Arcutis Biotherapeutics, Janssen, Allergan,
Almirall, AbbVie, Sol-Gel, Amgen, Regeneron, SanofiGenzyme, Pfizer, and AstraZeneca. Dr Armstrong has served
as research investigator and/or scientific advisor to AbbVie,
ASLAN, Boehringer Ingelheim, Bristol Myers Squibb, EPI,
Incyte, Leo Pharma, UCB Pharma, Janssen, Lilly, Novartis,
Ortho Dermatologics, Sun, Dermavant, Dermira Inc, Sanofi,
Regeneron, Pfizer, and Modmed. Dr Chiesa Fuxench has
served as a consultant for the Asthma and Allergy Foundation
of America and the National Eczema Association, Pfizer,
Incyte and AbbVie for which she received honoraria for
work related to atopic dermatitis; served as consultant for
Beiersdorf, which supported this work, has received research
grants from Regeneron, Sanofi, Tioga, Vanda, Menlo
Therapeutics, Leo Pharma, and Eli Lilly for work related to
atopic dermatitis; and has received honoraria for continuing
medical education work in atopic dermatitis sponsored by
educational grants from Regeneron and Sanofi. Dr Draelos
has served as a consultant for Beiersdorf. Dr Hamzavi has
served as an investigator (grant to institution) for Pfizer Inc,
Bayer, Lenicura, and Incyte, Estee Lauder, L’Oreal, Unigen,
Avita, Arcutis Biotherapeutics, and Ferndale Laboratories,
Inc; as an Advisory Board member for AbbVie; and as a
Consultant to Galderma Laboratories, LP, Incyte, Pfizer, UCB,
Boehringer Ingelheim, Beiersdorf, and Clarify Medical. Dr
Rigel has served as an advisor/consultant for Almirall,
Beiersdorf, Castle Biosciences, Inc, DermTech, Ferndale,
Johnson & Johnson, Myriad Genetics, Ortho Dermatologics,
Pfizer, and Scibase. Evince Communications has served as
scientific consultants for Beiersdorf, Inc, on educational
initiatives and the dermMentors Resident of Distinction
Award Program.
REFERENCES
1. Food and Drug Administration. Sunscreen: How to help
protect your skin from the sun. Updated November 2021.
Accessed December 27, 2021. https://www.fda.gov/drugs/
understanding-over-counter-medicines/sunscreen-how-helpprotect-your-skin-sun
2. Gasparro FP, Mitchnick M, Nash JF. A review of sunscreen
safety and efficacy. Photochem Photobiol. 1998;68(3):243-256.

Rigel et al S7

3. Mancuso JB, Maruthi R, Wang SQ, Lim HW. Sunscreens: an
update. Am J Clin Dermatol. 2017;18(5):643-650.
4. Ma Y, Yoo J. History of sunscreen: an updated view. J Cosmet
Dermatol. 2021;20(4):1044-1049.
5. Kligman AM. Early destructive effect of sunlight on human
skin. JAMA. 1969;210(13):2377-2380.
6. Liebel F, Kaur S, Ruvolo E, Kollias N, Southall MD. Irradiation of
skin with visible light induces reactive oxygen species and
matrix-degrading enzymes. J Invest Dermatol. 2012;132(7):
1901-1907.
7. Mahmoud BH, Ruvolo E, Hexsel CL, et al. Impact of longwavelength UVA and visible light on melanocompetent skin. J
Invest Dermatol. 2010;130(8):2092-2097.
8. Kollias N, Baqer A. An experimental study of the changes
in pigmentation in human skin in vivo with visible and
near infrared light. Photochem Photobiol. 1984;39(5):651659.
9. Regazzetti C, Sormani L, Debayle D, et al. Melanocytes sense
blue light and regulate pigmentation through opsin-3. J Invest
Dermatol. 2018;138(1):171-178.
10. Duteil L, Cardot-Leccia N, Queille-Roussel C, et al. Differences
in visible light-induced pigmentation according to wavelengths: a clinical and histological study in comparison with
UVB exposure. Pigment Cell Melanoma Res. 2014;27(5):822-826.
11. Boukari F, Jourdan E, Fontas E, et al. Prevention of melasma
relapses with sunscreen combining protection against UV and
short wavelengths of visible light: a prospective randomized
comparative trial. J Am Acad Dermatol. 2015;72(1):189-190.e1.
12. Kohli I, Chaowattanapanit S, Mohammad TF, et al. Synergistic
effects of long-wavelength ultraviolet A1 and visible light on
pigmentation and erythema. Br J Dermatol. 2018;178(5):11731180.
13. Kailas A, Solomon JA, Mostow EN, Rigel DS, Kittles R, Taylor SC.
Gaps in the understanding and treatment of skin cancer in
people of color. J Am Acad Dermatol. 2016;74(5):1020-1021.
14. Diffey BL, Osterwalder U, Herzog B. Suntanning with sunscreens: a comparison with sunbed tanning. Photodermatol
Photoimmunol Photomed. 2015;31(6):307-314.
15. Lim HW, Arellano-Mendoza MI, Stengel F. Current challenges
in photoprotection. J Am Acad Dermatol. 2017;76(3S1):S91S99.
16. Matsui MS, Hsia A, Miller JD, et al. Non-sunscreen photoprotection: antioxidants add value to a sunscreen. J Investig
Dermatol Symp Proc. 2009;14(1):56-59.
17. Wu Y, Matsui MS, Chen JZ, et al. Antioxidants add protection
to a broad-spectrum sunscreen. Clin Exp Dermatol. 2011;36(2):
178-187.
18. Maarouf M, Zullo SW, DeCapite T, Shi VY. Skin cancer
epidemiology and sun protection behaviors among Native
Americans. J Drugs Dermatol. 2019;18(5):420-423.
19. Alexis AF, Few J, Callender VD, et al. Myths and knowledge
gaps in the aesthetic treatment of patients with skin of color. J
Drugs Dermatol. 2019;18(7):616-622.
20. Cestari T, Arellano I, Hexsel D, Ortonne JP, Latin American
Pigmentary Disorders Academy. Melasma in Latin America:
options for therapy and treatment algorithm. J Eur Acad
Dermatol Venereol. 2009;23(7):760-772.
21. Wang SQ, Stanfield JW, Osterwalder U. In vitro assessments of
UVA protection by popular sunscreens available in the United
States. J Am Acad Dermatol. 2008;59(6):934-942.
22. Geisler AN, Austin E, Nguyen J, Hamzavi I, Jagdeo J, Lim HW.
Visible light. Part II: photoprotection against visible and
ultraviolet light. J Am Acad Dermatol. 2021;84(5):1233-1244.
23. Song H, Beckles A, Salian P, Porter ML. Sunscreen recommendations for patients with skin of color in the popular press and

S8 Rigel et al

24.

25.

26.

27.

in the dermatology clinic. Int J Womens Dermatol. 2021;7(2):
165-170.
Piquero-Casals J, Carrascosa JM, Morgado-Carrasco D, et al.
The role of photoprotection in optimizing the treatment of
atopic dermatitis. Dermatol Ther (Heidelb). 2021;11(2):315-325.
New York Magazine. The Strategist. The Best Sunscreens for
Your Face, According to Dermatologists. 2021. Accessed
December 27, 2021. https://nymag.com/strategist/article/
best-sunscreen-for-face.html
Buenger J, Driller H. Ectoin: an effective natural substance to
prevent UVA-induced premature photoaging. Skin Pharmacol
Physiol. 2004;17(5):232-237.
Chung JH, Lee SH, Youn CS, et al. Cutaneous photodamage in
Koreans: influence of sex, sun exposure, smoking, and skin
color. Arch Dermatol. 2001;137(8):1043-1051.

J AM ACAD DERMATOL

MARCH 2022

28. Passeron T, Lim HW, Goh CL, et al. Photoprotection according
to skin phototype and dermatoses: practical recommendations from an expert panel. J Eur Acad Dermatol Venereol.
2021;35(7):1460-1469.
29. Chen J, Shih J, Tran A, et al. Gender-based differences and
barriers in skin protection behaviors in melanoma survivors. J
Skin Cancer. 2016;2016:3874572.
30. Walburn J, Sainsbury K, Foster L, et al. Why? What? How?
Using an Intervention Mapping approach to develop a
personalised intervention to improve adherence to photoprotection in patients with xeroderma pigmentosum. Health
Psychol Behav Med. 2020;8(1):475-500.
31. Chauhan A, Gretz N. Role of visible light on skin melanoctyes: a systematic review. Photochem Photobiol. 2021;97(5):
911-915.

